biotech ai
30 articles about biotech ai in AI news
AI Firms Target Biotech for High-Impact, High-Margin Applications
A trend analysis notes AI companies are shifting focus to biotech, where accurate prediction models can be monetized through drug discovery and synthetic biology, creating a new competitive frontier.
Anthropic Acquires AI Biotech Coefficient Bio for ~$400M to Build 'Virtual Biologist'
Anthropic acquired AI biotech startup Coefficient Bio for approximately $400M. The small team was building AI to plan drug R&D, manage clinical strategy, and identify new drug opportunities, aligning with CEO Dario Amodei's vision of AI as a 'virtual biologist.'
The Coming Revolution: How AI-Powered Biotech Could Make Aging Obsolete Within Two Decades
Harvard geneticist David Sinclair predicts biotechnology advances will transform healthcare within 10-20 years, shifting from treating diseases to preventing and reversing aging itself through AI-driven biological control.
Anthropic Launches STEM Fellows Program to Pair Experts with AI Research
Anthropic announced the Anthropic STEM Fellows Program, a new initiative to bring science and engineering experts into its research teams for collaborative, months-long projects aimed at accelerating progress with AI.
OpenAI Launches GPT-Rosalind for Drug Discovery, GPT-5.4-Cyber for Security
OpenAI launched GPT-Rosalind, a life sciences model performing above the 95th percentile of human experts on novel biological data, and GPT-5.4-Cyber, a cybersecurity variant. These releases, alongside a major Agents SDK update, signal a pivot from general AI to specialized, high-stakes enterprise domains.
AI-Driven Age-Reversal Therapy Enters First Human Trials
An AI-discovered therapeutic approach for biological age reversal has advanced to its first human trials. This milestone validates the use of AI for identifying novel geroprotective compounds.
LABBench2 Benchmark Shows AI Biology Agents Struggle with Real-World Tasks
Researchers introduced LABBench2, a 1,900-task benchmark for AI in biology research. It shows current models perform 26-46% worse on realistic tasks versus simplified ones, exposing a critical capability gap.
AI-Reprogrammed Immune Cells Cure 3 Autoimmune Diseases in First Human Case
For the first time, a patient with three autoimmune diseases is in complete remission after doctors used AI to reprogram her own immune cells. This follows over a decade of requiring daily blood transfusions.
DeepMind's AlphaGenome AI Decodes Non-Coding DNA for CRISPR Targeting
Demis Hassabis states that while CRISPR can edit DNA, finding the right target is hard. DeepMind's AlphaGenome AI is analyzing the non-coding genome to predict mutation effects and guide precise CRISPR interventions.
Chamath Palihapitiya: SpaceX to Underpin AI-Driven Space Economy
Investor Chamath Palihapitiya stated that SpaceX's infrastructure will allow AI to rebuild every dimension of Earth's economy in space, creating vast new value layers.
Sam Altman Predicts 'One-Person Billion-Dollar Companies' as AI Reshapes Business Scale
OpenAI CEO Sam Altman predicts the emergence of 'one-person billion-dollar companies' powered by AI, citing a specific example from a private CEO discussion group. This follows his earlier forecast of 10-person billion-dollar firms, suggesting AI is accelerating the compression of business scale.
Eli Lilly Signs $2.75B AI Drug Discovery Deal with Insilico Medicine
Eli Lilly has entered a $2.75 billion licensing pact with Insilico Medicine for multiple AI-discovered drug programs. The deal includes an upfront payment, milestones, and royalties, marking a major validation for AI-driven pharmaceutical R&D.
China's Planar Maglev 'XBot' Movers Use AI for 6-DoF Precision on Electromagnetic 'Flyway'
Chinese robotics firm Planar Motor demonstrates 'XBot' movers that levitate 1–2 mm above a tiled electromagnetic surface, achieving frictionless, coordinated 2D motion. The system uses AI for 6-degree-of-freedom precision control in factory automation.
The Situation Game Launches Real-Time Market Instinct Test, Not an AI Trading Simulator
A new web-based game called The Situation tests players' market intuition in real-time against breaking news and a live crowd. It's a free, zero-chart psychological competition, not a trading simulator or AI model.
Kimi Launches 'Kimi Slides' AI Presentation Tool, Claims 5-Minute Investor Deck Creation
Moonshot AI's Kimi chatbot has launched a new feature called Kimi Slides that generates investor-ready presentations from messy notes in 5 minutes, positioning itself against professional design services.
Boston Consulting Group on 'Speaking Your AI Agent’s Language'
BCG highlights the critical need for effective human-AI agent communication as a cornerstone of digital transformation, particularly in complex, regulated industries like life sciences. This principle is broadly applicable to retail.
OpenAI's 'Autonomous AI Researchers' Vision Sparks Debate on Biology's 'ChatGPT Moment'
A tweet highlights OpenAI's repeated references to 'autonomous AI researchers' as signaling a 'ChatGPT moment for biology,' suggesting AI could accelerate drug discovery by orders of magnitude. The claim draws a direct analogy to AlphaFold's impact on structural biology.
Neurons Playing Doom: How Living Brain Cells Could Revolutionize Computing
Australian startup Cortical Labs is pioneering biological computing with a system that uses living human brain cells to perform computational tasks. Their CL1 computer consumes just 30 watts while learning to play Doom, potentially offering massive energy savings over traditional AI hardware.
Anthropic Challenges U.S. Government in Dual Lawsuits Over AI Research Restrictions
AI safety company Anthropic has filed lawsuits in two separate federal courts challenging U.S. government restrictions that have placed its research lab on an export blacklist. The legal action represents a significant confrontation between AI developers and regulatory authorities over research transparency and national security concerns.
The AI-Powered 'Cocktail': How One Injection Could Revolutionize Healthcare by 2029
A leading AI researcher predicts that within five years, personalized medical treatments delivered via single injections or pills will become reality. This breakthrough promises to democratize access to advanced healthcare through AI-driven drug discovery and delivery systems.
Safety Gap: OpenAI's Most Powerful AI Models Released Without Critical Risk Assessments
OpenAI's GPT-5.4 Pro, potentially the world's most capable AI for high-risk tasks like bioweapons research and cyber operations, has been released without published safety evaluations or system cards, continuing a concerning pattern with 'Pro' model releases.
China's Semiconductor Leaders Rally for National AI Chip Alliance Amid Tech War Escalation
China's top semiconductor executives have issued an unprecedented public call for a consolidated national effort to build AI chips, signaling a strategic shift toward self-reliance as U.S. export controls tighten. This coordinated push represents China's most direct response yet to technological containment efforts.
The AI IPO Showdown: OpenAI and Anthropic Prepare for Historic Public Debuts
OpenAI and Anthropic are reportedly planning IPOs in 2025, setting the stage for a historic battle between AI giants. Investors appear to be favoring Anthropic's long-term prospects despite OpenAI's current market dominance.
Beyond General AI: How Liquid Foundation Models Are Revolutionizing Drug Discovery
Researchers have developed MMAI Gym, a specialized training platform that teaches AI the 'language of molecules' to create more efficient drug discovery models. The resulting Liquid Foundation Models outperform larger general-purpose AI while requiring fewer computational resources.
Anthropic CEO Slams OpenAI's Pentagon Deal as 'Safety Theater' in Rare Industry Confrontation
Anthropic CEO Dario Amodei criticized OpenAI's Department of Defense AI partnership as 'safety theater' while revealing the Trump administration's hostility toward his company for refusing 'dictator-style praise.' The comments expose deepening fractures in AI governance approaches.
Top AI Researcher Max Schwarzer Departs OpenAI for Anthropic in Major Industry Shift
Prominent AI researcher Max Schwarzer has left OpenAI to join rival Anthropic, signaling intensifying competition for top talent in the AI sector. The move represents a significant personnel shift between two leading AI labs.
XtalPi's Profit Milestone Signals AI's Transformative Impact on Pharmaceutical Discovery
Chinese AI drug discovery firm XtalPi projects its first annual profit in 2025 following a 193% revenue surge, marking a pivotal moment for AI-driven pharmaceutical research. The company's turnaround demonstrates the commercial viability of AI in accelerating drug development pipelines.
The AI Scare Trade: How Market Fears Are Fueling an Unprecedented M&A Frenzy
A wave of AI-driven disruption is creating an 'AI scare trade' in capital markets, sparking fierce competition between traditional firms and AI startups. This has triggered a surge in mergers and acquisitions as companies race to adapt or acquire the technology reshaping entire industries.
AI Titans Unite: Sam Altman's Public Support for Anthropic Signals Industry-Wide Regulatory Push
OpenAI CEO Sam Altman has publicly declared solidarity with Anthropic amid government scrutiny, signaling unprecedented industry alignment on AI regulation. This coordinated stance could reshape how federal agencies approach oversight of rapidly advancing AI technologies.
FT's AI Risk Chart Sparks Debate: 50% Chance of Human Extinction Versus Abundance
A Financial Times chart showing AI could lead to either human extinction or unprecedented abundance has ignited debate about mainstream recognition of existential risks. The visualization presents a stark 50/50 probability between catastrophic and utopian outcomes.